Loading...
14 nigella sativa COVID-19 controlled studies, 10 RCTs
46% improvement
for early treatment, RR
0.54
[0.36-0.81]
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
HNS-COVID-PK
Ashraf (RCT)
82%
0.18 [0.04-0.80]
death
2/157
11/156
CT1
Improvement, RR [CI]
Treatment
Control
HNS-COVID-PK
Ashraf (RCT)
67%
0.33 [0.01-7.99]
death
0/107
1/103
CT1
HNS-COVID-PK
Ashraf (RCT)
79%
0.21 [0.05-0.92]
death
2/50
10/53
CT1
HNS-COVID-PK
Ashraf (RCT)
84%
0.16 [0.11-0.24]
no recov.
107 (n)
103 (n)
CT1
HNS-COVID-PK
Ashraf (RCT)
75%
0.25 [0.15-0.41]
no recov.
50 (n)
53 (n)
CT1
HNS-COVID-PK
Ashraf (RCT)
82%
0.18 [0.12-0.27]
viral+
107 (n)
103 (n)
CT1
HNS-COVID-PK
Ashraf (RCT)
77%
0.23 [0.14-0.38]
viral+
50 (n)
53 (n)
CT1
Al-Haidari (RCT)
96%
0.04 [0.00-0.70]
death
0/160
14/259
Al-Haidari (RCT)
93%
0.07 [0.02-0.30]
severe case
2/160
44/259
Aldwihi
24%
0.76 [0.54-1.03]
hosp.
85/345
152/393
Koshak (RCT)
75%
0.25 [0.03-2.22]
hosp.
1/91
4/92
Koshak (RCT)
43%
0.57 [0.42-0.78]
no recov.
34/91
60/92
BOSS-001
Bencheqr.. (DB RCT)
69%
0.31 [0.01-7.19]
hosp.
0/29
1/23
BOSS-001
Bencheqr.. (DB RCT)
9%
0.91 [0.48-1.72]
no improv.
28 (n)
23 (n)
BOSS-001
Bencheqr.. (DB RCT)
35%
0.65 [0.29-1.43]
no improv.
28 (n)
23 (n)
BOSS-001
Bencheqr.. (DB RCT)
43%
0.57 [0.22-1.43]
viral+
5/21
8/19
Said (RCT)
77%
0.23 [0.04-1.23]
recovery
30 (n)
30 (n)
Said (RCT)
89%
0.11 [0.02-0.58]
recovery
30 (n)
30 (n)
Said (RCT)
80%
0.20 [0.07-0.59]
no recov.
30 (n)
30 (n)
Said (RCT)
77%
0.23 [0.07-0.70]
no recov.
30 (n)
30 (n)
Said (RCT)
85%
0.15 [0.04-0.48]
no recov.
30 (n)
30 (n)
Said (RCT)
90%
0.10 [0.03-0.33]
no recov.
30 (n)
30 (n)
Said (RCT)
85%
0.15 [0.02-0.74]
no recov.
30 (n)
30 (n)
Said (RCT)
67%
0.33 [0.05-1.79]
no recov.
30 (n)
30 (n)
Said (RCT)
58%
0.42 [0.08-1.86]
no recov.
30 (n)
30 (n)
Said (RCT)
58%
0.42 [0.08-1.86]
no recov.
30 (n)
30 (n)
Said (RCT)
82%
0.18 [0.02-0.94]
no recov.
30 (n)
30 (n)
Said (RCT)
86%
0.14 [0.02-0.70]
no recov.
30 (n)
30 (n)
Said (RCT)
27%
0.73 [0.22-2.40]
no recov.
30 (n)
30 (n)
Said (RCT)
56%
0.44 [0.12-1.53]
no recov.
30 (n)
30 (n)
Said (RCT)
80%
0.20 [0.03-0.92]
no recov.
30 (n)
30 (n)
Said (RCT)
90%
0.10 [0.01-0.66]
no recov.
30 (n)
30 (n)
Said (RCT)
61%
0.39 [0.13-1.08]
viral+
30 (n)
30 (n)
Said (RCT)
85%
0.15 [0.04-0.51]
viral+
30 (n)
30 (n)
Said (RCT)
91%
0.09 [0.02-0.30]
viral+
30 (n)
30 (n)
Said (RCT)
87%
0.13 [0.03-0.45]
viral+
30 (n)
30 (n)
Idris
39%
0.61 [0.44-0.84]
recov. time
26 (n)
25 (n)
Idris
15%
0.85 [0.25-2.82]
viral+
3/13
6/22
Idris
40%
0.60 [0.39-0.91]
viral+
13/26
21/25
Karimi (RCT)
51%
0.49 [0.09-2.66]
death
2/192
4/189
CT1
Karimi (RCT)
61%
0.39 [0.08-2.00]
ICU
2/192
5/189
CT1
Karimi (RCT)
70%
0.30 [0.15-0.61]
hosp.
184 (n)
174 (n)
CT1
Karimi (RCT)
67%
0.33 [0.17-0.65]
no recov.
184 (n)
174 (n)
CT1
Karimi (RCT)
14%
0.86 [0.80-0.93]
no recov.
184 (n)
174 (n)
CT1
Setayesh (RCT)
-8%
1.08 [0.07-16.7]
death
1/38
1/41
CT1
Setayesh (RCT)
27%
0.73 [0.58-0.92]
oxygen time
38 (n)
41 (n)
CT1
Setayesh (RCT)
29%
0.71 [0.63-0.81]
hosp. time
38 (n)
41 (n)
CT1
Faruq (RCT)
6%
0.94 [0.63-1.38]
death
29/75
31/75
ICU patients
Faruq (RCT)
62%
0.38 [0.18-0.81]
ventilation
8/75
21/75
ICU patients
Faruq (RCT)
83%
0.17 [0.05-0.54]
ventilation
3/75
18/75
ICU patients
Faruq (RCT)
23%
0.77 [0.22-2.67]
ICU
4/46
5/44
ICU patients
Faruq (RCT)
28%
0.72 [0.34-1.53]
ICU
9/46
12/44
ICU patients
Faruq (RCT)
34%
0.66 [0.49-0.90]
ICU
25/46
36/44
ICU patients
Faruq (RCT)
7%
0.93 [0.83-1.05]
ICU
41/46
42/44
ICU patients
Al-Haidari
62%
0.38 [0.31-0.46]
symp. case
68/188
180/188
Shehab
0%
1.00 [0.36-2.74]
severe case
4/39
22/214
Chandra (RCT)
49%
0.51 [0.16-1.59]
cases
4/52
8/53
CT1
Chandra (RCT)
87%
0.13 [0.02-0.84]
cases
1/51
8/53
CT1
Chandra (RCT)
74%
0.26 [0.06-1.17]
cases
2/51
8/53
CT1
Daneshfard (RCT)
34%
0.66 [0.49-0.89]
symp. case
37/89
53/84
CT1
Daneshfard (RCT)
97%
0.03 [0.00-0.19]
symp. case
1/89
35/84
CT1
Daneshfard (RCT)
66%
0.34 [0.11-1.04]
symp. case
4/89
11/84
CT1
Daneshfard (RCT)
62%
0.38 [0.12-1.16]
symp. case
4/89
10/84
CT1
Daneshfard (RCT)
26%
0.74 [0.50-1.09]
symp. case
29/89
37/84
CT1
Daneshfard (RCT)
-6%
1.06 [0.43-2.62]
symp. case
9/89
8/84
CT1
Daneshfard (RCT)
79%
0.21 [0.07-0.59]
symp. case
4/89
18/84
CT1
Daneshfard (RCT)
76%
0.24 [0.09-0.60]
symp. case
5/89
20/84
CT1
Daneshfard (RCT)
98%
0.02 [0.00-0.31]
symp. case
0/89
25/84
CT1
Nigella sativa COVID-19 outcomes
c19 early .org
December 2024
1 CT: study uses combined treatment
Favors nigella sativa
Favors control
Figure S2. Comparison of results for RCTs versus observational studies.
For COVID-19 treatments, there is no significant difference between the results of RCTs and observational studies. Observational studies do not systematically over or underestimate efficacy. For high-cost treatments, there is a non-significant trend towards RCTs showing greater efficacy.
Please send us corrections, updates, or comments.
c19early involves the extraction of 100,000+ datapoints from
thousands of papers.
Community updates
help ensure high accuracy.
Treatments and other interventions are complementary.
All practical, effective, and safe
means should be used based on risk/benefit analysis.
No treatment or intervention is 100% available and effective for all current
and future variants.
We do not provide medical advice. Before taking any medication,
consult a qualified physician who can provide personalized advice and details
of risks and benefits based on your medical history and situation.
FLCCC and
WCH
provide treatment protocols.
Submit